"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

Liraglutide is currently sold only in an injectable form under the brand names Saxenda® and Victoza®, both manufactured by Novo Nordisk®. Despite the launch of a genericized injected version of ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Medicare is preparing to negotiate prices on GLP-1 drugs such as Ozempic. Novo Nordisk investors could see the news put $14.3 billion in Medicare revenue at risk. Viking Therapeutics stock ...